Crossmark

Investigating efficacy of “microbiota modulation of the gut-lung Axis” combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial

Crossref DOI link: https://doi.org/10.1186/s12885-021-08448-6

Published Online: 2021-06-22

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xia, Qing

Chen, Guojie

Ren, Yanbei

Zheng, Tiansheng

Shen, Changxing

Li, Ming

Chen, Xiangyun

Zhai, Hong

Li, Zhuang

Xu, Jianfang

Gu, Aiqin

Jin, Meiling

Fan, Lihong
Funding

Funding for this research was provided by:

Shanghai Shen Kang Hospital Development Center (SHDC12018119)
License Information

Text and Data Mining valid from 2021-06-22

Version of Record valid from 2021-06-22
More Information

Article History

Received: 6 December 2020

Accepted: 4 June 2021

First Online: 22 June 2021

Declarations

:

: The trial has received ethics approval from the Ethics Committee of Shanghai 10th people’s Hospital (SHSY-IEC-KY-4.0/18–177/01), Shanghai Pulmonary Hospital(K-18-169),and Shanghai Chest Hospital (KS(Y)1885). All participants provide full informed consent to participate inthe trial.

: Not applicable.

: There is no conflict of interest.

Document is current

Any future updates will be listed below